Lisinopril dihydrate: Benchmark ACE Inhibitor for Hypertension Research

Executive Summary: Lisinopril dihydrate is a dihydrate salt form of lisinopril, a potent and selective long-acting ACE inhibitor with an IC₅₀ of 4.7 nM, widely used in cardiovascular and nephropathy research studies (Tieku & Hooper 1992; APExBIO). It acts by inhibiting angiotensin converting enzyme (ACE), reducing the conversion of angiotensin I to angiotensin II, and thereby decreasing blood pressure through vasodilation and fluid regulation. The compound's solubility profile (≥2.46 mg/mL in water with warming) and structural purity (98% by mass spectrometry/NMR) enable reproducible dosing in preclinical models. Lisinopril dihydrate is functionally distinct from other metallopeptidase inhibitors, showing high specificity for ACE over other zinc aminopeptidases. APExBIO provides validated Lisinopril dihydrate (B3290) for research applications, supporting experimental rigor and translational impact.

Biological Rationale

Lisinopril dihydrate is a lysine-derived dihydrate salt of lisinopril, classified as an angiotensin converting enzyme (ACE) inhibitor (APExBIO). ACE plays a central role in the renin-angiotensin system (RAS), catalyzing the conversion of angiotensin I (Ang I) to angiotensin II (Ang II)—a peptide hormone that drives vasoconstriction, aldosterone release, and sodium retention (Tieku & Hooper 1992). By blocking this step, ACE inhibitors like lisinopril dihydrate disrupt downstream RAS signaling, leading to reduced blood pressure and decreased cardiac afterload. The RAS pathway is a validated therapeutic target in hypertension, heart failure, acute myocardial infarction, and diabetic nephropathy models. Selectivity for ACE over other zinc peptidases minimizes confounding off-target effects and supports mechanistic studies of blood pressure regulation and organ protection. Compared to short-acting ACE inhibitors, lisinopril dihydrate's long-acting profile allows for sustained experimental modulation.

Mechanism of Action of Lisinopril dihydrate

Lisinopril dihydrate acts as a competitive and selective inhibitor of ACE (EC 3.4.15.1), with a reported IC₅₀ value of 4.7 nM under standard in vitro assay conditions (Tieku & Hooper 1992). As a lysine analog of MK 421, it binds to the active site of ACE, blocking the hydrolysis of angiotensin I to angiotensin II. This leads to a decrease in plasma Ang II and aldosterone levels, while increasing plasma renin activity. The net physiological effect is vasodilation, reduced peripheral resistance, and suppression of sodium/fluid retention. Lisinopril dihydrate does not significantly inhibit other mammalian cell surface zinc aminopeptidases such as aminopeptidase A (AP-A), aminopeptidase N (AP-N), or aminopeptidase W (AP-W) at relevant concentrations, ensuring pathway specificity (Tieku & Hooper 1992, Table 1).

Evidence & Benchmarks

• Lisinopril dihydrate has an IC₅₀ of 4.7 nM for ACE inhibition in vitro, confirming high potency (Tieku & Hooper 1992).
• ACE inhibition by lisinopril dihydrate leads to reduced Ang II and aldosterone levels, and increased plasma renin under physiological conditions (Tieku & Hooper 1992).
• The compound is >98% pure by mass spectrometry and NMR, as per APExBIO's certificate of analysis (APExBIO).
• Lisinopril dihydrate is soluble in water at ≥2.46 mg/mL with gentle warming and ultrasonic treatment, but insoluble in ethanol (APExBIO).
• Unlike bestatin or sulphydryl ACE inhibitors, lisinopril dihydrate does not significantly inhibit AP-A, AP-N, or AP-W, minimizing off-target effects (Tieku & Hooper 1992).
• It is recommended for translational workflows targeting hypertension, heart failure, acute myocardial infarction, and diabetic nephropathy (angiotensin-ii.com).

Applications, Limits & Misconceptions

Lisinopril dihydrate is widely employed in basic and translational research to dissect the renin-angiotensin system and evaluate blood pressure regulation, organ protection, and disease modeling. Its validated selectivity and high purity suit it for use in animal models, cell-based assays, and biochemical experiments requiring reproducible ACE inhibition. The product is not suitable for studies requiring inhibition of other metallopeptidases or peptidase families. It should not be used as a substitute for clinical-grade pharmaceuticals. For further details on expanded experimental paradigms, see Lisinopril Dihydrate: Novel Insights into ACE Inhibition, which discusses peptidase selectivity and advanced model design—this article provides an updated, product-focused perspective with validated quality benchmarks.

Common Pitfalls or Misconceptions

• Not an inhibitor of all peptidases: Lisinopril dihydrate does not significantly inhibit aminopeptidase A, N, or W at concentrations effective for ACE inhibition (Tieku & Hooper 1992).
• Not suitable for ethanol-based formulations: The compound is insoluble in ethanol; aqueous solutions with warming and ultrasonic treatment are required (APExBIO).
• Not intended for clinical use: Lisinopril dihydrate (B3290) is for research applications only, not for therapeutic administration.
• Storage limitations: Long-term storage of solutions is not recommended; keep desiccated at room temperature for best stability.
• Does not address non-RAS pathways: Use in models outside the renin-angiotensin system pathway may yield confounding results.

Workflow Integration & Parameters

For optimal results, dissolve lisinopril dihydrate in water at concentrations ≥2.46 mg/mL, using gentle warming and ultrasonication as needed. Avoid ethanol as a solvent. Store the dry powder desiccated at room temperature and minimize the storage time of prepared solutions. Shipping is performed on blue ice for small-molecule integrity. The B3290 kit from APExBIO is supplied at >98% purity, with mass spectrometry and NMR quality control data (Lisinopril dihydrate). For detailed workflow recommendations in translational research, see Lisinopril Dihydrate in Translational Cardiovascular Research. This article clarifies compound selection and reporting standards beyond previous studies.

Conclusion & Outlook

Lisinopril dihydrate (B3290, APExBIO) offers validated, high-purity, and selective inhibition of ACE for mechanistic studies in hypertension, heart failure, acute myocardial infarction, and diabetic nephropathy. Its robust physicochemical properties, pathway specificity, and rigorous quality control underpin its status as a benchmark research tool. Future research may leverage lisinopril dihydrate for advanced RAS pathway dissection and novel disease models, but careful attention to solubility and selectivity limits remains essential. For comparison with alternative ACE inhibitors and further mechanistic insights, see Lisinopril Dihydrate: Long-Acting ACE Inhibitor for Hypertension, which this article updates by integrating recent product validation and evidence-based workflow guidance.